Lung Cancer in the Netherlands

Lizza E.L. Hendriks; Anne Marie C. Dingemans; Dirk K.M. De Ruysscher; Mieke J. Aarts; Lidia Barberio; Robin Cornelissen; Koen J. Hartemink; Michel van den Heuvel; Ed Schuuring; Hans J.M. Smit; Anthonie J. van der Wekken; Egbert F. Smit

doi:10.1016/j.jtho.2020.10.012

Lung Cancer in the Netherlands

Lizza E.L. Hendriks^*
, Anne Marie C. Dingemans
, Dirk K.M. De Ruysscher
, Mieke J. Aarts
, Lidia Barberio
, Robin Cornelissen
, Koen J. Hartemink
, Michel van den Heuvel
, Ed Schuuring
, Hans J.M. Smit
, Anthonie J. van der Wekken
, Egbert F. Smit

^*Corresponding author for this work

Pulmonary Medicine

GROW - School for Oncology and Reproduction
Netherlands Comprehensive Cancer Organization (IKNL)
Patient Foundation Lung Cancer Netherlands
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Radboud University Medical Center
University Medical Centre Groningen
Rijnstate Hospital

Research output: Contribution to journal › Editorial › Academic › peer-review

20 Citations (Scopus)

Abstract

As described in the Lung Cancer Europe position article, the health care quality in the Netherlands is at a good level.50 Recent improvements include the organization of oncologic care in CCNs, centralization of specialist care, multidisciplinary tumor boards, and MTBs and the initiation of proton radiotherapy. Hospitals and CCNs can learn from each other on how to optimize care. National guidelines are in place for most tumor types and are frequently updated. As the treatment of lung cancer is becoming increasingly complex, discussions are also ongoing on how to optimize the training of physicians to deliver optimal lung cancer care. Nationwide studies in thoracic oncology, also with multidisciplinary collaboration, have been well-accruing for most indications. Initiatives (mobile applications) are also ongoing or already in place to provide easy access for health care providers and patients to rapidly identify ongoing trials throughout the Netherlands. Importantly, numerous challenges lie ahead, including the increasing demand to justify reimbursement of novel treatments and diagnostic tests, the continuing smoke prevention policy, and the necessity to acquire legislation for the initiation of lung cancer screening.

Original language	English
Pages (from-to)	355-365
Number of pages	11
Journal	Journal of Thoracic Oncology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/j.jtho.2020.10.012
Publication status	Published - Mar 2021

Bibliographical note

Funding Information:
There is an active Dutch lung cancer patient organization: Longkanker Nederland ( www.longkankernederland.nl ). This organization is committed to saving lives and accelerating lung cancer research and policy while empowering people living with, or at risk for, lung cancer. Longkanker Nederland conducts awareness campaigns, attacks the stigma of the disease, and advocates for more urgency and more funds for lung cancer research. It furthermore gives information to and organizes information days for patients and their relatives. It is funded through a national cancer fund, the Ministry of Health, and donors and sponsors.

Funding Information:
Stefanie Hofstede and Marjolein Moret-Hartman from the Dutch Knowledge Institution (Kennisinstituut) are acknowledged for providing Figure 2A and B. The authors are grateful to the Dutch Institute of Clinical Auditing for providing the data for the surgical part.

Funding Information:
Disclosure: Dr. Hendriks reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Hendriks reports receiving research funding from Roche Genentech, Boehringer Ingelheim, and AstraZeneca (all paid to the institution); has a role on the advisory board of Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Roche Genentech, Pfizer, Takeda, Merck Sharp & Dohme, Boehringer Ingelheim, and Amgen (all paid to the institution); has a role as a speaker in Merck Sharp & Dohme; reports receiving travel/conference reimbursement from Roche Genentech (self); has a role in mentorship program with key opinion leaders funded by AstraZeneca; reports receiving fees for educational webinars from Quadia (self), interview sessions funded by Roche Genentech (paid to the institution), and as local PI of clinical trials of AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, and Janssen Pharmaceuticals. Dr. Dingemans reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Dingemans has a role on the advisory boards and/or lectures for Roche Genentech, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Pfizer, Bristol-Myers Squibb, Amgen, Novartis, Merck Sharp & Dohme, Takeda, and Pharma Mar (all paid to the institution); and reports receiving research support from Bristol-Myers Squibb, AbbVie, and Amgen (all paid to the institution). Dr. De Ruysscher reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. De Ruysscher reports receiving research funding from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Olink (all paid to the institution); and has a role on the advisory board of Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Philips, Cellgene, Seattle Genetics, Roche Genentech, Merck, and Pfizer (all paid to the institution). Dr. Aarts reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Aarts reports receiving research grant from Amgen. Dr. Cornelissen reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Cornelissen reports receiving speaker fees from Roche, Bristol-Myers Squibb, and Pfizer and has a role on the advisory board of Roche and Merck Sharp & Dohme. Dr. Schuuring reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Schuuring reports receiving advisory board and travel expenses from Biocartis, Bristol-Myers Squibb, AstraZeneca, Pfizer, Bayer, Illumina, Janssen Cilag, Agena Biosciences, Novartis, and MSK/Merck (all paid to the institution); reports receiving research grants from CC Diagnostics and Boehringer Ingelheim; and reports receiving travel expenses from Roche Genentech. Dr. van der Wekken reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. van der Wekken reports receiving research grants and personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, and Takeda (all paid to the institution). The remaining authors declare no conflict of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC OR-01

Access to Document

10.1016/j.jtho.2020.10.012

Cite this

@article{0038f3750cab44fa95fa6849206f975a,

title = "Lung Cancer in the Netherlands",

abstract = "As described in the Lung Cancer Europe position article, the health care quality in the Netherlands is at a good level.50 Recent improvements include the organization of oncologic care in CCNs, centralization of specialist care, multidisciplinary tumor boards, and MTBs and the initiation of proton radiotherapy. Hospitals and CCNs can learn from each other on how to optimize care. National guidelines are in place for most tumor types and are frequently updated. As the treatment of lung cancer is becoming increasingly complex, discussions are also ongoing on how to optimize the training of physicians to deliver optimal lung cancer care. Nationwide studies in thoracic oncology, also with multidisciplinary collaboration, have been well-accruing for most indications. Initiatives (mobile applications) are also ongoing or already in place to provide easy access for health care providers and patients to rapidly identify ongoing trials throughout the Netherlands. Importantly, numerous challenges lie ahead, including the increasing demand to justify reimbursement of novel treatments and diagnostic tests, the continuing smoke prevention policy, and the necessity to acquire legislation for the initiation of lung cancer screening.",

author = "Hendriks, \{Lizza E.L.\} and Dingemans, \{Anne Marie C.\} and \{De Ruysscher\}, \{Dirk K.M.\} and Aarts, \{Mieke J.\} and Lidia Barberio and Robin Cornelissen and Hartemink, \{Koen J.\} and \{van den Heuvel\}, Michel and Ed Schuuring and Smit, \{Hans J.M.\} and \{van der Wekken\}, \{Anthonie J.\} and Smit, \{Egbert F.\}",

note = "Funding Information: There is an active Dutch lung cancer patient organization: Longkanker Nederland ( www.longkankernederland.nl ). This organization is committed to saving lives and accelerating lung cancer research and policy while empowering people living with, or at risk for, lung cancer. Longkanker Nederland conducts awareness campaigns, attacks the stigma of the disease, and advocates for more urgency and more funds for lung cancer research. It furthermore gives information to and organizes information days for patients and their relatives. It is funded through a national cancer fund, the Ministry of Health, and donors and sponsors. Funding Information: Stefanie Hofstede and Marjolein Moret-Hartman from the Dutch Knowledge Institution (Kennisinstituut) are acknowledged for providing Figure 2A and B. The authors are grateful to the Dutch Institute of Clinical Auditing for providing the data for the surgical part. Funding Information: Disclosure: Dr. Hendriks reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Hendriks reports receiving research funding from Roche Genentech, Boehringer Ingelheim, and AstraZeneca (all paid to the institution); has a role on the advisory board of Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Roche Genentech, Pfizer, Takeda, Merck Sharp \& Dohme, Boehringer Ingelheim, and Amgen (all paid to the institution); has a role as a speaker in Merck Sharp \& Dohme; reports receiving travel/conference reimbursement from Roche Genentech (self); has a role in mentorship program with key opinion leaders funded by AstraZeneca; reports receiving fees for educational webinars from Quadia (self), interview sessions funded by Roche Genentech (paid to the institution), and as local PI of clinical trials of AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp \& Dohme/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, and Janssen Pharmaceuticals. Dr. Dingemans reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Dingemans has a role on the advisory boards and/or lectures for Roche Genentech, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Pfizer, Bristol-Myers Squibb, Amgen, Novartis, Merck Sharp \& Dohme, Takeda, and Pharma Mar (all paid to the institution); and reports receiving research support from Bristol-Myers Squibb, AbbVie, and Amgen (all paid to the institution). Dr. De Ruysscher reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. De Ruysscher reports receiving research funding from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Olink (all paid to the institution); and has a role on the advisory board of Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Philips, Cellgene, Seattle Genetics, Roche Genentech, Merck, and Pfizer (all paid to the institution). Dr. Aarts reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Aarts reports receiving research grant from Amgen. Dr. Cornelissen reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Cornelissen reports receiving speaker fees from Roche, Bristol-Myers Squibb, and Pfizer and has a role on the advisory board of Roche and Merck Sharp \& Dohme. Dr. Schuuring reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Schuuring reports receiving advisory board and travel expenses from Biocartis, Bristol-Myers Squibb, AstraZeneca, Pfizer, Bayer, Illumina, Janssen Cilag, Agena Biosciences, Novartis, and MSK/Merck (all paid to the institution); reports receiving research grants from CC Diagnostics and Boehringer Ingelheim; and reports receiving travel expenses from Roche Genentech. Dr. van der Wekken reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. van der Wekken reports receiving research grants and personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, and Takeda (all paid to the institution). The remaining authors declare no conflict of interest.",

year = "2021",

month = mar,

doi = "10.1016/j.jtho.2020.10.012",

language = "English",

volume = "16",

pages = "355--365",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Lung Cancer in the Netherlands

AU - Hendriks, Lizza E.L.

AU - Dingemans, Anne Marie C.

AU - De Ruysscher, Dirk K.M.

AU - Aarts, Mieke J.

AU - Barberio, Lidia

AU - Cornelissen, Robin

AU - Hartemink, Koen J.

AU - van den Heuvel, Michel

AU - Schuuring, Ed

AU - Smit, Hans J.M.

AU - van der Wekken, Anthonie J.

AU - Smit, Egbert F.

N1 - Funding Information: There is an active Dutch lung cancer patient organization: Longkanker Nederland ( www.longkankernederland.nl ). This organization is committed to saving lives and accelerating lung cancer research and policy while empowering people living with, or at risk for, lung cancer. Longkanker Nederland conducts awareness campaigns, attacks the stigma of the disease, and advocates for more urgency and more funds for lung cancer research. It furthermore gives information to and organizes information days for patients and their relatives. It is funded through a national cancer fund, the Ministry of Health, and donors and sponsors. Funding Information: Stefanie Hofstede and Marjolein Moret-Hartman from the Dutch Knowledge Institution (Kennisinstituut) are acknowledged for providing Figure 2A and B. The authors are grateful to the Dutch Institute of Clinical Auditing for providing the data for the surgical part. Funding Information: Disclosure: Dr. Hendriks reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Hendriks reports receiving research funding from Roche Genentech, Boehringer Ingelheim, and AstraZeneca (all paid to the institution); has a role on the advisory board of Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Roche Genentech, Pfizer, Takeda, Merck Sharp & Dohme, Boehringer Ingelheim, and Amgen (all paid to the institution); has a role as a speaker in Merck Sharp & Dohme; reports receiving travel/conference reimbursement from Roche Genentech (self); has a role in mentorship program with key opinion leaders funded by AstraZeneca; reports receiving fees for educational webinars from Quadia (self), interview sessions funded by Roche Genentech (paid to the institution), and as local PI of clinical trials of AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, and Janssen Pharmaceuticals. Dr. Dingemans reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Dingemans has a role on the advisory boards and/or lectures for Roche Genentech, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Pfizer, Bristol-Myers Squibb, Amgen, Novartis, Merck Sharp & Dohme, Takeda, and Pharma Mar (all paid to the institution); and reports receiving research support from Bristol-Myers Squibb, AbbVie, and Amgen (all paid to the institution). Dr. De Ruysscher reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. De Ruysscher reports receiving research funding from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Olink (all paid to the institution); and has a role on the advisory board of Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Philips, Cellgene, Seattle Genetics, Roche Genentech, Merck, and Pfizer (all paid to the institution). Dr. Aarts reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Aarts reports receiving research grant from Amgen. Dr. Cornelissen reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Cornelissen reports receiving speaker fees from Roche, Bristol-Myers Squibb, and Pfizer and has a role on the advisory board of Roche and Merck Sharp & Dohme. Dr. Schuuring reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Schuuring reports receiving advisory board and travel expenses from Biocartis, Bristol-Myers Squibb, AstraZeneca, Pfizer, Bayer, Illumina, Janssen Cilag, Agena Biosciences, Novartis, and MSK/Merck (all paid to the institution); reports receiving research grants from CC Diagnostics and Boehringer Ingelheim; and reports receiving travel expenses from Roche Genentech. Dr. van der Wekken reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. van der Wekken reports receiving research grants and personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, and Takeda (all paid to the institution). The remaining authors declare no conflict of interest.

PY - 2021/3

Y1 - 2021/3

N2 - As described in the Lung Cancer Europe position article, the health care quality in the Netherlands is at a good level.50 Recent improvements include the organization of oncologic care in CCNs, centralization of specialist care, multidisciplinary tumor boards, and MTBs and the initiation of proton radiotherapy. Hospitals and CCNs can learn from each other on how to optimize care. National guidelines are in place for most tumor types and are frequently updated. As the treatment of lung cancer is becoming increasingly complex, discussions are also ongoing on how to optimize the training of physicians to deliver optimal lung cancer care. Nationwide studies in thoracic oncology, also with multidisciplinary collaboration, have been well-accruing for most indications. Initiatives (mobile applications) are also ongoing or already in place to provide easy access for health care providers and patients to rapidly identify ongoing trials throughout the Netherlands. Importantly, numerous challenges lie ahead, including the increasing demand to justify reimbursement of novel treatments and diagnostic tests, the continuing smoke prevention policy, and the necessity to acquire legislation for the initiation of lung cancer screening.

AB - As described in the Lung Cancer Europe position article, the health care quality in the Netherlands is at a good level.50 Recent improvements include the organization of oncologic care in CCNs, centralization of specialist care, multidisciplinary tumor boards, and MTBs and the initiation of proton radiotherapy. Hospitals and CCNs can learn from each other on how to optimize care. National guidelines are in place for most tumor types and are frequently updated. As the treatment of lung cancer is becoming increasingly complex, discussions are also ongoing on how to optimize the training of physicians to deliver optimal lung cancer care. Nationwide studies in thoracic oncology, also with multidisciplinary collaboration, have been well-accruing for most indications. Initiatives (mobile applications) are also ongoing or already in place to provide easy access for health care providers and patients to rapidly identify ongoing trials throughout the Netherlands. Importantly, numerous challenges lie ahead, including the increasing demand to justify reimbursement of novel treatments and diagnostic tests, the continuing smoke prevention policy, and the necessity to acquire legislation for the initiation of lung cancer screening.

UR - https://www.scopus.com/pages/publications/85101604267

U2 - 10.1016/j.jtho.2020.10.012

DO - 10.1016/j.jtho.2020.10.012

M3 - Editorial

C2 - 33641718

SN - 1556-0864

VL - 16

SP - 355

EP - 365

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 3

ER -

Lung Cancer in the Netherlands

Abstract

Bibliographical note

UN SDGs

Research programs

Access to Document

Other files and links

Fingerprint

Cite this